MLPR As A Diagnostic Marker For Acute Pulmonary Embolism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

37 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-01

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A retrospective study to assess the utility of hematological marker (monocyte to large platelet ratio) to diagnose patients with pulmonary embolism

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Magnetic Resonance Diagnosis of Pulmonary Embolism

NCT01077778

Lung Diseases Pulmonary Embolism

TERMINATED

Role of MRI in Diagnosis of Pulmonary Embolism

NCT03754673

Pulmonary Embolism

COMPLETED

Surfactant Associated Protein - A Novel Marker for the Diagnosis of Pulmonary Embolism

NCT01353365

Pulmonary Embolism

UNKNOWN

Prognostic Value of Plasma Lactate Levels Among Patients With Acute Pulmonary Embolism

NCT01908231

Pulmonary Embolism

COMPLETED

Magnetic Resonance Imaging Combined With Venous Ultrasonography of the Legs for Pulmonary Embolism

NCT02059551

Pulmonary Embolism

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators conducted a retrospective review of emergency department records of patients who presented with signs and symptoms suggestive of pulmonary embolism (PE) and underwent CT pulmonary angiography (CTPA) for diagnosis. Hematological laboratory findings obtained prior to any treatment were collected and compared between two groups based on CTPA results: those with confirmed PE (CT positive) and those without PE (CT negative).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Embolism (Diagnosis) Diagnosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary embolism

Group that is confirmed to have pulmonary embolism by positive CTPA finding filling defect.

Monocyte to Large Platelet Ratio (MLPR)

Intervention Type DIAGNOSTIC_TEST

Admission laboratory values were used to calculate the Monocyte-to-Large Platelet Ratio (MLPR) by dividing the absolute monocyte count by the large platelet count. These values were obtained from blood samples collected before any treatment was administered.

Non-Pulmonary embolism

Group that have pulmonary embolism diagnosis was excluded by negative CTPA finding.

Monocyte to Large Platelet Ratio (MLPR)

Intervention Type DIAGNOSTIC_TEST

Admission laboratory values were used to calculate the Monocyte-to-Large Platelet Ratio (MLPR) by dividing the absolute monocyte count by the large platelet count. These values were obtained from blood samples collected before any treatment was administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monocyte to Large Platelet Ratio (MLPR)

Admission laboratory values were used to calculate the Monocyte-to-Large Platelet Ratio (MLPR) by dividing the absolute monocyte count by the large platelet count. These values were obtained from blood samples collected before any treatment was administered.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Only patients with the results of full blood count and white blood cell differentiation, measured before the treatment of suspected PE.
* Patients underwent CT pulmonary angiography to confirm or exclude pulmonary embolism diagnosis.

Exclusion Criteria

* Patient with history of any myeloproliferative disorder, myelofibrosis, Glanzmann thrombasthenia, May-Hegglin anomaly, Bernard-Soulier syndrome, suspicion of disseminated intravascular coagulation.
* Patient receiving any anticoagulant drug at a therapeutic dose.
* Patient with blood transfusion in the last 2 months.
* Patients with acute coronary syndrome, pulmonary edema.
* Patient on immunosuppressive drugs , Oral contraceptive pills .
* Patients with severe renal or hepatic disease.
* Patients with Stroke.
* Patients with malignancy.

Eligible Sex

ALL

Accepts Healthy Volunteers

No